Literature DB >> 31376374

Overcoming Challenges of Implementing Closed System Transfer Device Clinical In-Use Compatibility Testing for Drug Development of Antibody Drug Conjugates.

Frankie Petoskey1, Stanley C Kwok2, William Jackson2, Shan Jiang2.   

Abstract

Closed system transfer devices (CSTD) are a supplemental engineering control designed to reduce occupational exposure of hazardous drugs and are currently implemented in accordance with evolving regulations. Owing to the novelty and complexity of these devices and their importance in clinical in-use testing, here we evaluated FDA-approved CSTD, assessing product quality through stability indicating assays to determine any drug product incompatibilities. Six devices were used in a simulated compounding and administration of a late-phase IgG1 antibody-drug conjugate (ADC) and the resulting samples were analyzed for visible and subvisible particle counts by light obscuration and micro-flow imaging, physical stability by size exclusion chromatography, and biological activities by relative potency. Potential challenges included improper fit of CSTD components, loss of product to void volume, and material incompatibility. Results showed compatibility of the ADC with the 6 CSTD evaluated. One CSTD introduced subvisible particles into the ADC during compounding that were identified through morphological assessment as silicone oil. This study highlights the importance of clinical in use testing with new devices and proposes strategies to mitigate the risk of drug product incompatibility with CSTD.
Copyright © 2020 American Pharmacists Association®. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  antibody drug conjugate(s) (ADC); clinical trial simulation(s); drug delivery system(s); monoclonal antibody(s); particle morphology; physical stability; protein aggregation; protein formulation(s); stability

Mesh:

Substances:

Year:  2019        PMID: 31376374     DOI: 10.1016/j.xphs.2019.07.021

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  4 in total

1.  Evaluation of Different Quality-Relevant Aspects of Closed System Transfer Devices (CSTDs).

Authors:  Ahmed Besheer; Hanns-Christian Mahler; Anja Matter-Schwald; Sergio Mompart Barrenechea; Martin Vogt; Pascal Chalus; Pauline Heymes; Timothy Pillow; Andrea Kirste; Patrick Favrod; Susanne Joerg; Roman Mathaes
Journal:  Pharm Res       Date:  2020-04-09       Impact factor: 4.200

2.  Frequency and component analysis of contaminants generated in preparation of anticancer agents using closed system drug transfer devices (CSTDs).

Authors:  Satomi Sumikawa; Yoshihiro Yakushijin; Kenjiro Aogi; Takuya Yano; Chiyuki Tsukui; Tadashi Noguchi; Taro Shiraishi; Yasuhiro Horikawa; Yasuo Yasuoka; Akihiro Tanaka; Noriaki Hidaka; Mamoru Tanaka
Journal:  Sci Rep       Date:  2022-01-07       Impact factor: 4.379

3.  Fcγ Receptor-Dependent Internalization and Off-Target Cytotoxicity of Antibody-Drug Conjugate Aggregates.

Authors:  Michihiko Aoyama; Minoru Tada; Hidetomo Yokoo; Yosuke Demizu; Akiko Ishii-Watabe
Journal:  Pharm Res       Date:  2021-12-27       Impact factor: 4.200

4.  Closed-system transfer device use with oncology biologics: A survey of Canadian healthcare practitioners.

Authors:  Manmeet Khaira; Allison L Guy
Journal:  J Oncol Pharm Pract       Date:  2021-05-18       Impact factor: 1.416

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.